CytomX Therapeutics CTMX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$59.14M-242% | -$17.37M-154% | $28.02M— | $47.98M— | $41.6M— | ||
| $9M+15.8% | $6.3M-17.8% | $6.71M-19.5% | $7.32M-3.3% | $7.77M-3.6% | ||
| —— | —— | -$1.72M— | —— | —— | ||
| $1.09M— | $221K— | -$695K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$31.14M+76.8% | -$66.15M+44.1% | -$101.7M+5.0% | -$128.19M-27.3% | -$133.93M-33.2% | ||
| $147K+0.7% | $146K0.0% | $146K0.0% | $146K0.0% | $146K0.0% | ||
| -$80.09M+1.4% | -$75.59M+12.3% | -$72.25M+18.2% | -$77.43M+9.8% | -$81.23M+11.2% | ||
| —— | —— | —— | $245K-49.6% | $314K-65.4% | ||
| $415.52M+137% | $192.52M+23.8% | $198.09M-9.0% | $190.72M-36.0% | $175.28M-37.0% | ||
| $132.5M-49.2% | $133M-47.9% | $168M-46.8% | $178.5M-46.7% | $261M-18.4% | ||
| -$283.56M-432% | -$60.18M-160% | -$30.63M— | -$12.46M— | $85.41M— | ||
| $338.01M+4,919% | $109.66M+1,487% | $95.47M+1,667% | $95.47M+1,667% | $6.74M+816% | ||
| $344.93M+4,594% | $110.45M+1,368% | $96.05M+1,641% | $95.8M+172% | $7.35M-75.8% | ||
| -$18.28M— | -$24.89M— | —— | —— | —— | ||
| $2.48M-36.4% | $2.21M-58.5% | $2.27M-66.3% | $2.86M-61.7% | $3.9M-49.7% | ||
| $147K+0.7% | $146K0.0% | $146K0.0% | $146K0.0% | $146K0.0% | ||
| $1.1M-28.9% | $1.23M-24.2% | $1.13M-33.2% | $1.43M-18.4% | $1.54M-19.0% | ||
| —— | -$402K-279% | -$328K-313% | -$254K-379% | -$180K-579% | ||
| —— | —— | -$9.09M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$4.53M-8.5% | -$4.48M-9.8% | -$4.38M-9.7% | -$4.28M-9.7% | -$4.18M-9.6% | ||
| $415.52M+137% | $192.52M+23.8% | $198.09M-9.0% | $190.72M-36.0% | $175.28M-37.0% | ||
| $132.5M-49.2% | $133M-47.9% | $168M-46.8% | $178.5M-46.7% | $261M-18.4% | ||
| $1.09M+149% | $811K+32.3% | $613K-9.1% | $360K-46.6% | $439K-40.3% | ||
| —— | —— | —— | —— | —— | ||
| -$31.14M+76.8% | -$66.15M+44.1% | -$101.7M+5.0% | -$128.19M-27.3% | -$133.93M-33.2% | ||
| —— | $3M— | $2.25M— | $1.5M— | $750.5K— | ||
| —— | —— | —— | —— | —— | ||
| -$80.19M+1.7% | -$75.81M+12.4% | -$72.35M+18.5% | -$77.68M+10.0% | -$81.54M+11.7% | ||
| -$80.19M+1.7% | -$75.81M+12.4% | -$72.35M+18.5% | -$77.68M+10.0% | -$81.54M+11.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CytomX Therapeutics generate?
- CytomX Therapeutics (CTMX) generated -$80.1M in operating cash flow over the trailing twelve months.
- What is CytomX Therapeutics's free cash flow?
- After $347.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$80.2M over the trailing twelve months, up 1.7% year over year.
- Where does CytomX Therapeutics's cash flow data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
